Significant Ownership of TCG Crossover GP II, LLC

Large-stake snapshot 1 signal
Large-stake filing summary
  • Recent SEC Schedule 13D/G filings for TCG Crossover GP II, LLC focus on large-stake beneficial ownership disclosures and amendments.
  • Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
Manager Names, identifiers, and filing context for this profile. 2 identity fields
Manager signature
/s/ Craig Skaling - Craig Skaling, Authorized Signatory
Manager location
Palo Alto, CA

Follow Filing Activity

Follow TCG Crossover GP II, LLC with Pro and return when a new Schedule 13D/G filing changes the record on this page.

Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.

Review Pro alert access Already have an account? Sign in and return here

Significant Ownership of TCG Crossover GP II, LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
SRZN Surrozen, Inc. Common Stock, par value $0.0001 per share 13% $43,986,796 +$5,944,857 1,473,101 +16% Chen Yu 31 Mar 2026
VOR Vor Biopharma Inc. Common Stock, par value $0.0001 per share 10% $8,623,079 5,673,078 Chen Yu 30 Mar 2026
RAPT RAPT Therapeutics, Inc. Common Stock, $0.0001 par value per share 10% $11,478,006 13,193,110 TCG Crossover GP II, LLC 27 Dec 2024
VTGN Vistagen Therapeutics, Inc. Common Stock, par value $0.001 per share 10% $2,343,167 4,100,029 Chen Yu 31 Mar 2026
AURA Aura Biosciences, Inc. Common Stock, par value $0.00001 per share 9.9% $64,540,664 9,533,333 Chen Yu 05 May 2026
IPSC Century Therapeutics, Inc. Common Stock, par value $0.0001 per share 9.9% $15,978,987 17,754,430 Chen Yu 09 Jan 2026
ALXO ALX Oncology Holdings Inc. Common Stock, par value $0.001 per share 9.9% $14,703,389 13,011,849 Chen Yu 30 Jan 2026
ALT Altimmune, Inc. Common Stock, par value $0.0001 per share 9.8% $67,600,000 20,000,000 Chen Yu 24 Apr 2026
ADCT ADC Therapeutics SA Common Shares, par value CHF $0.08 per share 9.2% $42,143,648 11,390,175 TCG Crossover GP II, LLC 27 Oct 2025
ALEC Alector, Inc. Common Stock, par value $0.0001 per share 9.2% $29,600,000 10,000,000 Chen Yu 22 Oct 2025
ADVM Adverum Biotechnologies, Inc. Common Stock, par value $0.0001 per share 8.9% 1,871,482 TCG Crossover GP II, LLC 31 Mar 2025
TNGX Tango Therapeutics, Inc. Common Stock, par value $0.001 per share 8.1% $242,624,658 -$40,252,214 11,597,737 -14% TCG Crossover GP II, LLC 31 Mar 2026
AVTX Avalo Therapeutics, Inc. Common Stock, par value $0.001 per share 7.9% $43,476,699 3,017,120 TCG Crossover GP II, LLC 05 May 2026
FULC Fulcrum Therapeutics, Inc. Common Stock, par value $0.001 per share 7.9% $40,267,500 5,250,000 TCG Crossover GP II, LLC 31 Mar 2026
CATX Perspective Therapeutics, Inc. Common Stock, $0.001 par value 6.9% $21,767,809 7,915,567 Chen Yu 03 Feb 2026
LBRX LB Pharmaceuticals Inc. Common Stock, par value $0.0001 per share 6.4% $44,773,162 +$2,299,497 1,839,489 +5.4% TCG Crossover GP II, LLC 31 Mar 2026
TECX Tectonic Therapeutic, Inc. Common Stock, $0.0001 par value per share 6.2% $24,202,334 1,169,760 Chen Yu 12 Feb 2026
AMLX Amylyx Pharmaceuticals Inc. Common Stock, $0.0001 par value per share 5.7% $74,863,306 6,243,812 TCG Crossover GP II, LLC 31 Dec 2025
GLUE Monte Rosa Therapeutics, Inc. Common Stock, par value $0.0001 per share 5.5% $80,795,199 +$3,398,916 4,622,151 +4.4% Chen Yu 31 Mar 2026
ZLAB Zai Lab Limited Ordinary Shares, par value $0.000006 per share 5.3% $1,210,406,452 59,130,750 Chen Yu 02 Jun 2026
DNTH Dianthus Therapeutics, Inc. Common Stock, par value $0.001 per share 4.7% $32,660,322 1,501,624 TCG Crossover GP II, LLC 31 Mar 2025
EYPT Eyepoint, Inc. Common Stock, $0.001 par value per share 4.3% $62,265,799 3,572,335 TCG Crossover GP II, LLC 31 Dec 2025
CDTX Cidara Therapeutics, Inc. Common Stock, par value $0.0001 per share 0% $0 0 TCG Crossover GP II, LLC 30 Sep 2025
NKTR Nektar Therapeutics, Inc. Common Stock, par value $0.0001 per share 0% $0 -$110,015,928 0 -100% TCG Crossover GP II, LLC 30 Sep 2025

Schedules 13D/G Reported by TCG Crossover GP II, LLC:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .